The invention concerns a device for the atraumatic transfer of a material or substance with a reproductive, therapeutic or diagnostic purpose into a female mammal, comprising a body assembly, an outer sheath suitable for being inserted as far as the start of one of the uterine horns, an inner sheath inside the outer sheath and capable of being extended into the uterine horn, and a piston inserted into the inner sheath order to push the material or substance up to the distal end of the inner sheath. The body assembly comprises a rod extending away from the outer sheath, and on which a shuttle assembly is slidingly mounted, comprising a primary shuttle, mounted sliding on said rod and to which the piston is attached, and a secondary shuttle, mounted sliding on said primary shuttle and to which the inner sheath is attached.

The invention concerns a device for the atraumatic transfer of a material or substance with a reproductive, therapeutic or diagnostic purpose into a female mammal, comprising a body assembly, an outer sheath suitable for being inserted as far as the start of one of the uterine horns, an inner sheath inside the outer sheath and capable of being extended into the uterine horn, and a piston inserted into the inner sheath order to push the material or substance up to the distal end of the inner sheath. The body assembly comprises a rod extending away from the outer sheath, and on which a shuttle assembly is slidingly mounted, comprising a primary shuttle, mounted sliding on said rod and to which the piston is attached, and a secondary shuttle, mounted sliding on said primary shuttle and to which the inner sheath is attached.

Provided are ex vivo and in vivo methods utilizing therapeutic genes for treatment of male and female infertility, including non-obstructive azoospermia (NOA) and premature ovarian insufficiency (POI) and comorbid diseases, with or without transmitting the therapeutic gene to offspring of the infertile subject. Germline gene therapy methods are also described to reduce or eliminate disease from families with or without transmission of the therapeutic gene to offspring.

Provided are ex vivo and in vivo methods utilizing therapeutic genes for treatment of male and female infertility, including non-obstructive azoospermia (NOA) and premature ovarian insufficiency (POI) and comorbid diseases, with or without transmitting the therapeutic gene to offspring of the infertile subject. Germline gene therapy methods are also described to reduce or eliminate disease from families with or without transmission of the therapeutic gene to offspring.

Everting balloon systems and methods for using the same are disclosed herein. The systems can be configured to access and dilate body lumen and cavities. For example, the systems can be used to dilate the cervix and access the uterine cavity. The systems can also be used to occlude the cervix. The systems can also be used to occlude the urethra.

Everting balloon systems and methods for using the same are disclosed herein. The systems can be configured to access and dilate body lumen and cavities. For example, the systems can be used to dilate the cervix and access the uterine cavity. The systems can also be used to occlude the cervix. The systems can also be used to occlude the urethra.

The present invention is drawn to novel methods of selecting mammals receptive to embryo transfers in order to improve reproductive efficiency and milk production of the mammals. The present invention encompasses three methods: (1) selecting from any group of mammals; (2) selecting from estrus-negative mammals; and (3) selecting from estrus-negative mammals and pooling the selected mammals with estrus-positive mammals. Also encompassed is a kit for selecting mammals receptive to embryo transfers.

The present invention is drawn to novel methods of selecting mammals receptive to embryo transfers in order to improve reproductive efficiency and milk production of the mammals. The present invention encompasses three methods: (1) selecting from any group of mammals; (2) selecting from estrus-negative mammals; and (3) selecting from estrus-negative mammals and pooling the selected mammals with estrus-positive mammals. Also encompassed is a kit for selecting mammals receptive to embryo transfers.

The present invention provides PiggyBac transposase proteins, nucleic acids encoding the same, compositions comprising the same, kits comprising the same, non-human transgenic animals comprising the same, and methods of using the same.

The present invention provides PiggyBac transposase proteins, nucleic acids encoding the same, compositions comprising the same, kits comprising the same, non-human transgenic animals comprising the same, and methods of using the same.